An open-label, randomized, 2-period crossover, drug interaction study to evaluate the potential pharmacokinetic interaction between multiple doses of ketoconazole and a single dose of HKI-272 [neratinib] administered orally to healthy subjects.

Trial Profile

An open-label, randomized, 2-period crossover, drug interaction study to evaluate the potential pharmacokinetic interaction between multiple doses of ketoconazole and a single dose of HKI-272 [neratinib] administered orally to healthy subjects.

Completed
Phase of Trial: Phase I

Latest Information Update: 11 May 2012

At a glance

  • Drugs Ketoconazole; Neratinib
  • Indications Breast cancer
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Wyeth
  • Most Recent Events

    • 11 May 2012 Actual end date (Nov 2006) added as reported by ClinicalTrials.gov.
    • 11 May 2012 Company (Puma Biotechnology) added as reported by ClinicalTrials.gov.
    • 21 Mar 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top